Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men. Early detection is key to successful treatment but men often dodge the doctor, avoiding diagnosis ...
Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...
Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...
Dr Oliver Hulson discusses an advanced AI software system being piloted in Leeds to help improve prostate cancer diagnosis ...
Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial. This is an ASCO Meeting Abstract from the 2016 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results